Physiological functions of poly(ADP-ribose) polymerase and potential clinical applications of its inhibitors

Abstract

Abstract: Poly(ADP-ribose)polymerases(PARP)is one of the most important enzymes in human body.It plays an vital role in chromatin relaxation, signal transduction, DNA damage repair and apoptosis.Its over-activation induces necrosis and pathological processes.Therefore, inhibition of PARP may provide potential therapeutic approaches to treatment of a variety of diseases.This review presents an overview of PARP's functions and potential clinical applications of PARP inhibitors.

Key words: poly (ADP-ribose)polymerase, inhibitor, DNA damage repair, cell necrosis

CLC Number:

R969

WANG Hui-yuan, SUN Hong-bin. Physiological functions of poly(ADP-ribose) polymerase and potential clinical applications of its inhibitors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 743-747.

References

1 Tentori L, Portarena I, Graziani G.Potential clinical applications of poly(ADP-ribose)polymerase inhibitors[J].Pharmacol Res, 2002;45:73-85.
2 Jagtap P, Szabo C.Poly(ADP-ribose)polymerase and the therapeutic effects of its inhibitors[J].Nat Rev Drug Discov, 2005; 4:421-440.
3 Hanai S, Uchida M, Kobayashi S, et al.Genomic organization of Drosophila poly(ADP-ribose)polymerase and distribution of its mRNA during development[J].J Boil Chem, 1998;273: 11881-11886.
4 Nguewa PA, Fuertes MA, Valladares B, et al.Poly(ADP-ribose) polymerases:homology, structural domains and functions.Novel therapeutical applications[J].Prog Biophys Mol Biol, 2005;88:143-172.
5 Davidovic L, Vodenicharov M, Affar EB, et al.Importance of poly(ADP-ribose)glycohydrolase in the control of poly(ADP-ribose) metabolism[J].Exp Cell Res, 2001;268:7-13.
6 Kun E, Bauer PI.Cell biological functions of PARP I:an overview[J].Ital J Biochem, 2001;50:15-18.
7 Yung TM, Sato S, Satoh MS.Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose)polymerase-1-topoisomerase I interaction[J]. J Biol Chem, 2004;279:39686-39696.
8 Flohr C, Burkle A, Radicella JP, et al.Poly(ADP-ribosyl) ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein[J].Nucleic Acids Res, 2003;31:5332-5337.
9 von Kobbe C, Harrigan JA, Schreiber V, et al.Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase activities of the Werner syndrome protein[J].Nucleic Acids Res, 2004;32:4003-4014.
10 Virag L, Szabo C.The therapeutic potential of poly(ADP-ribose) polymerase inhibitors[J].Pharmacol Rev, 2002;54:375-429.
11 Ota K, Kameoka M, Tanaka Y, et al.Expression of histone acetyltransferases was downregulated in poly(ADP-ribose)polymerase-1-deficient murine cells[J].Biochem Biophys Res Commun, 2003;310:312-317.
12 Herceg Z, Wang ZQ.Failure of poly(ADP-ribose)polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis[J].Mol Cell Biol, 1999;19:5124-5133.
13 Szabo G, Liaudet L, Hagl S, et al.Poly(ADP-ribose)polymerase activation in the reperfused myocardium[J].Cardiovas Res, 2004;61:471-480.
14 Casey PJ, Black JH, Szabo C, et al.Poly(adenosine diphosphate ribose)polymerase inhibition modulates spinal cord dysfunction after thoracoabdominal aortic ischemia-reperfusion[J]. J Vasc Surg, 2005;41:99-107.
15 Hua HT, Albadawi H, Entabi F, et al.Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion[J].Arch Surg, 2005;140: 344-351.
16 Szabo G, Bahrle S, Sivanandam V, et al.Immunomodulatory effects of poly(ADP-ribose) polymerase inhibition contribute to improved cardiac function and survival during acute cardiac rejection[J].J Heart Lung Transplant, 2006;25:794-804.
17 Kiss L, ChenM, Gero D, et al.Effects of 7-ketocholesterol on the activity of endothelial poly(ADP-ribose)polymerase and on endothelium-dependent relaxant function[J].Int J Mol Med, 2006;18:1113-1117.
18 Rajesh M, Mukhopadhyay P, Godlewski G, et al.Poly(ADPribose) polymerase inhibition decreases angiogenesis[J].Biochem Biophys Res Commun, 2006;350:1056-1062.
19 Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis[J].Biochem J, 2005;386:119-125.
20 Farmer H, McCabe N, Lord CJ, et al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J]. Nature, 2005;434:917-921.
21 Bryant HE, Schultz N, Thomas HD, et al.Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase[J].Nature, 2005;434:913-917.
22 Calabrese CR, Almassy R, Barton S, et al.Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361[J].J Natl Cancer Inst, 2004;96:56-67.
23 Stone DH, Al-Badawi H, Conrad MF, et al.PJ34, a poly-ADP-ribose polymerase inhibitor, modulates renal injury after thoracic aortic ischemia reperfusion[J].Surgery, 2005;138: 368-374.
24 Lobo SM, Orrico SR, QueirozMM, et al.Pneumonia-induced sepsis and gut injury:effects of a poly-(ADP-ribose) polymerase inhibitor[J].J Surg Res, 2005;129:292-297.
25 Gibson TM, Cotter MA, Cameron NE.Effects of poly(ADP-ribose) polymerase inhibition on dysfunction of non-adrenergic non-cholinergic neurotransmission in gastric fundus in diabetic rats[J].Nitric Oxide, 2006;15:344-350.
26 Nguewa PA, FuertesMA, Cepeda V, et al.Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells[J].Med Chem, 2006;2:47-53.
27 Geraets L, Moonen HJ,Wouters EF, et al.Caffeine metabolites are inhibitors of the nuclear enzyme poly (ADP-ribose)polymerase-1 at physiological concentrations[J].Biochem Pharmacol, 2006;72:902-910.
28 Pacher P, Liaudet L, Mabley JG, et al.Beneficial effects of a novel ultrapotent poly(ADP-ribose)polymerase inhibitor in murine models of heart failure[J].Int J Mol Med, 2006;17:369-375.

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	WANG Juan, LIU Weiying, YE Yucai, FU Wenli, ZHANG Sha, LI Leping. Research progress of norepinephrine reuptake inhibitor combined with antimuscarinic in the treatment of obstructive sleep apnea [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 714-720.
[3]	SHEN Jiaqing, LIU Yi. Mechanism of tyrosine kinase 2 inhibitors in treatment of plaque psoriasis and their progress in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 323-330.
[4]	LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi . PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 355-360.
[5]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[6]	WANG Jinhuo, GAO Xinyue, GUO Jianrong. Effect of COX-2 inhibitors on postoperative delirium in elderly patients undergoing orthopedic surgery and its possible mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 863-869.
[7]	HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun. Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
[8]	SUN Ying, YU Qin. Research progress on the imbalance of coagulation and fibrinolysis system and the pathogenesis and treatment of idiopathic pulmonary interstitial fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 689-695.
[9]	LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi. Integrins targeting αv are used as drug targets for pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 709-714.
[10]	PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
[11]	WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming. Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
[12]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[13]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[14]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
[15]	YAO Yao, XIA Min, HOU Cong, HE Airong. Effects of ABT-737 on the growth and angiogenesis of ovarian cancer cells in the co-culture of TAMs and SKOV3 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 144-153.